This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2016 by Jonsson Comprehensive Cancer Center
Sponsor:
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01990196
First received: November 5, 2013
Last updated: June 12, 2017
Last verified: September 2016
  Purpose
Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated with hormone therapy plus drugs that directly target cancer cells.

Condition Intervention Phase
Prostate Cancer Drug: degarelix Drug: enzalutamide Drug: trametinib Drug: dasatinib Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Randomized, Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Jonsson Comprehensive Cancer Center:

Primary Outcome Measures:
  • N-cadherin and vimentin expression [ Time Frame: Prostatectomy will occur during the 2 week "window" between 6 and 8 weeks after enrollment ]
    The primary outcome of N-cadherin and vimentin expression will be measured in post-treatment RP specimens. Comparisons amongst the various treatment groups (post-treatment inter-group) will be performed after all data have been collected.


Estimated Enrollment: 45
Actual Study Start Date: September 23, 2014
Estimated Study Completion Date: September 30, 2019
Estimated Primary Completion Date: September 30, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: AR inhibition only

AR inhibition only Group 1: degarelix + enzalutamide

Endocrine therapy with degarelix and enzalutamide will continue for a minimum of 6 weeks and a maximum of 8 weeks in all groups prior to the planned prostatectomy.

Drug: degarelix

Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Other Names:
  • Firmagon
  • FE200486
Drug: enzalutamide

Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Other Names:
  • Xtandi
  • MDV3100
Active Comparator: AR inhibition plus MEK inhibition

AR inhibition plus MEK inhibition Group 2: trametinib + degarelix + enzalutamide

In Group 2, treatment with trametinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, trametinib will be administered for no less than two weeks and no more than four weeks.

Drug: degarelix

Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Other Names:
  • Firmagon
  • FE200486
Drug: enzalutamide

Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Other Names:
  • Xtandi
  • MDV3100
Drug: trametinib

Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician

Other Name: Mekinist
Active Comparator: AR inhibition plus SRC inhibition

AR inhibition plus SRC inhibition Group 3: dasatinib + degarelix + enzalutamide

In Group 3, treatment with dasatinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, dasatinib will be administered for no less than two weeks and no more than four weeks.

Drug: degarelix

Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Other Names:
  • Firmagon
  • FE200486
Drug: enzalutamide

Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician.

Other Names:
  • Xtandi
  • MDV3100
Drug: dasatinib

Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.

Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician

Other Names:
  • Sprycel
  • BMS-354825

Detailed Description:
Most prostate cancers respond to hormone therapy, also known as chemical castration. Unfortunately, castration resistance may occur in certain prostate cancers. Castration resistance or hormone refractory prostate cancer means that the cancer continues to progress as seen by progressively rising PSA and/or or an increase in tumor mass on bone scan, X-ray, CT scan or MRI despite previous hormonal therapy. The researchers are interested in understanding mechanisms of castration resistance in prostate cancer by analyzing prostate tissue before radical prostatectomy (from prostate biopsy tissue) and after radical prostatectomy (whole prostate specimen). They will look at the "molecular signature" of prostate cancer cells after hormone therapy to identify the key steps that the cancer cells undergo to become resistant to hormone therapy. In addition, the researchers will use other medications in addition to hormone therapy in order to block some of the key biochemical steps that are thought to mediate treatment resistance. This research will provide crucial information for the development of therapies that can improve the clinical outcome of patients with advanced prostate cancer.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (patients must meet all of the following inclusion criteria to participate in this study)

  1. Willing and able to give informed consent.
  2. Adenocarcinoma of the prostate with planned RP with curative intent as part of standard of care management plan.
  3. Patient is a candidate for radical prostatectomy.
  4. Tumor accessible to biopsy.
  5. Age ≥ 18 years.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  7. Estimated life expectancy of ≥ 6 months,
  8. Adequate organ function: normal renal, liver, hematologic, coagulation and cardiac function:

    1. Absolute neutrophil count > 1,500/µL, or platelet count > 100,000/µL, or hemoglobin > 5.6 mmol/L (9 g/dL) at the Screening visit,
    2. Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) within the normal range at the Screening visit,
    3. Creatinine < 1.5 mg/dL at the Screening visit,
    4. INR < 1.3 (or < 3 if on warfarin or other anticoagulants) at the Screening visit,
    5. Albumin > 30 g/L (3.0 g/dL) at the Screening visit,
    6. Left ventricular ejection fraction (LVEF) ≥ LLN by ECHO or MUGA,
  9. Patients with clinically localized adenocarcinoma of the prostate who are scheduled to undergo radical prostatectomy (RP) with curative intent and have the following clinico-pathologic features: (1) Gleason score sum ≥ 4+3 or any Gleason 5, (2) PSA > 20, (3) clinical stage ≥ T3a (staging by MRI is allowed).
  10. Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels,
  11. Willing to abstain from procreative sex or partake in appropriate form of contraception. For the purpose of this study, condom use or abstinence will be required.

Exclusion Criteria (all candidates meeting any of the following exclusion criteria will be excluded from participation in the study)

  1. Any prior treatment for prostate cancer,
  2. Any non-adenocarcinoma histologic component,
  3. Any evidence of lymphatic or hematogenous metastases,
  4. Clinically significant cardiovascular disease including:

    1. LVEF < LLN
    2. History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months,
    3. Uncontrolled angina within 3 months,
    4. Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or patients with history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multi-gated acquisition scan performed within 3 months results in a left ventricular ejection fraction that is ≥ 45%,
    5. Any history of congestive heart failure of any NYHA class for patients assigned to Group 2 (trametinib arm).
    6. History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes),
    7. Patients with intra-cardiac defibrillators or permanent pacemakers,
    8. Hypotension as indicated by systolic blood pressure < 86 millimeters of mercury (mmHg) at the Screening visit,
    9. Bradycardia as indicated by a heart rate of < 50 beats per minute on the Screening ECG,
    10. Treatment refractory hypertension defined as a blood pressure of systolic > 140 mmHG and/or diastolic > 90 mmHG which cannot be controlled by anti-hypertensive therapy,
    11. QTC ≥ 480 milliseconds,
    12. Known cardiac metastases.
  5. Presence of a comorbid disease or medical condition that would impair the ability of the patient to receive or comply with the study protocol,
  6. History of interstitial lung disease or pneumonitis,
  7. History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):

    • History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes).
    • Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:

      • Evidence of new optic disc cupping
      • Evidence of new visual field defects
      • Intraocular pressure > 21 mm Hg
  8. Evidence of a coagulopathy,
  9. Patient receiving therapeutic anticoagulation.
  10. Unwillingness to engage in adequate contraception,
  11. Allergy/sensitivity to any study drug (degarelix, enzalutamide, trametinib, dasatinib), or drugs chemically related to study drug, or excipients or to dimethylsulfoxide.
  12. Prior use of degarelix, enzalutamide, trametinib, or dasatinib in any context,
  13. Known or suspected brain metastasis or active leptomeningeal disease or spinal cord compression.
  14. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted).
  15. History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past,
  16. History of loss of consciousness or transient ischemic attack within past 12 months,
  17. Prior use of androgen deprivation therapy or radiation therapy,
  18. Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last 3 months),
  19. Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 30 days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days of enrollment,
  20. Hospitalization within 30 days of enrollment,
  21. History of another malignancy within the previous 5 years other than curatively treated non-melanoma skin cancer,
  22. Use of an investigational agent within 4 weeks of enrollment,
  23. Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g., saw palmetto) or systemic corticosteroids greater than the equivalent of 10 mg of prednisone per day within 4 weeks of enrollment,
  24. Use of any medications known to affect the serum androgen levels or the PSA,
  25. Any condition or reason that, in the opinion of the Investigator, interferes with the ability of the patient to participate in the trial, which places the patient at undue risk, or complicates the interpretation of safety data.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01990196

Locations
United States, California
University of California, Los Angeles Recruiting
Los Angeles, California, United States, 90095
Contact: David Choi, MPH    310-206-7168    dechoi@mednet.ucla.edu   
Principal Investigator: Matthew Rettig, MD         
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: Matthew Rettig, M.D. University of California, Los Angeles
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT01990196     History of Changes
Other Study ID Numbers: 13-000714
Study First Received: November 5, 2013
Last Updated: June 12, 2017

Keywords provided by Jonsson Comprehensive Cancer Center:
prostate cancer
hormone therapy
radical prostatectomy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Trametinib
Dasatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 24, 2017